| Drug Name |
Midostaurin |
| Drug ID |
BADD_D02453 |
| Description |
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. |
| Indications and Usage |
Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). |
| Marketing Status |
Not Available |
| ATC Code |
L01EX10 |
| DrugBank ID |
DB06595
|
| KEGG ID |
D05029
|
| MeSH ID |
C059539
|
| PubChem ID |
9829523
|
| TTD Drug ID |
D07NVU
|
| NDC Product Code |
55361-0016; 46016-1200; 68554-0126; 71796-021; 54893-0094; 52076-6262; 71796-018; 68254-0021 |
| Synonyms |
midostaurin | benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-N-methyl-, (8alpha,9beta,10beta,12alpha)- | 4'-N-benzoylstaurosporine | benzoylstaurosporine | 4'-N-benzoyl staurosporine | N-((9S,10R,11R,13R)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1H,9H-diindolo(1,2,3-GH:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methylbenzamide | PKC412 | PKC 412 | PKC-412 | Rydapt | CGP 41251 | CGP 41 251 | CGP-41251 |
